Michael Castine, MD
Medical Oncology · Baton Rouge, LANPI 1205814092
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $127,899 of the $164,667 with a category attached, or 77.7%. 60 manufacturers reported payments, led by Takeda Pharmaceuticals U.S.A., Inc. at 42.0% of the total. Reporting peaked in 2019 at $86,190 and has fallen 96.2% since, to $3,260 in 2025.
Across 1,120 payments — averaging $147.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$69K
- Exelixis Inc.$39K
- AstraZeneca$27K
- GSK$7K
- E.r. Squibb & Sons, L.L.C.$4K
- Novartis$1K
- plus $16K from 54 others
Across 508 payments — averaging $5062.52 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$526K
- Genentech, Inc.$369K
- AstraZeneca$303K
- AbbVie$251K
- Merck$201K
- Eli Lilly$201K
- plus $721K from 16 others
What the payments were for
- Consulting fees$3,6522%
- Speaking & faculty fees$127,89978%
- Travel & lodging$11,4097%
- Food & beverage$20,28412%
- Education$1,4241%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few medical oncology providers in Louisianato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 94 | $1,486,899 |
| CabometyxCabozantinib S-Malate | 36 | $814,404 |
| JakafiRuxolitinib Phosphate | 56 | $770,425 |
| PomalystPomalidomide | 29 | $659,281 |
| VenclextaVenetoclax | 71 | $436,294 |
| XtandiEnzalutamide | 37 | $377,547 |
| Lenalidomide | 29 | $352,509 |
| CalquenceAcalabrutinib Maleate | 24 | $329,579 |
| ErleadaApalutamide | 26 | $294,911 |
| TagrissoOsimertinib Mesylate | 17 | $285,220 |
| NinlaroIxazomib Citrate | 20 | $282,816 |
| KisqaliRibociclib Succinate | 23 | $277,754 |
| NubeqaDarolutamide | 18 | $239,827 |
| BosulifBosutinib | 12 | $235,989 |
| SprycelDasatinib | 13 | $227,059 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $644 | $1,486,89994 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel | $4,275 | $886,34042 claims |
| Exelixis Inc.Cabometyx | $39,268 | $814,40436 claims |
| Incyte CorporationJakafi | $316 | $770,42556 claims |
| AstraZenecaCalquence, Tagrisso | $26,524 | $614,79941 claims |
| NovartisKisqali, Tasigna, Gleevec | $1,397 | $570,84655 claims |
| AbbVieVenclexta | $379 | $436,29471 claims |
| Astellas Pharma US IncXtandi | $513 | $377,54737 claims |
| Johnson & JohnsonErleada, Xarelto | $1,340 | $345,78586 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Ninlaro | $69,188 | $282,81620 claims |
| PfizerBosulif, Eliquis, Premarin | $1,032 | $277,51983 claims |
| BayerNubeqa | $539 | $239,82718 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few medical oncology providers in Louisianaon file to place this against a meaningful peer group, so we don't.
Other medical oncology in Baton Rouge
- Gerald MiletelloBaton Rouge$26K
- Pavani EllipeddiBaton Rouge$11K
- Cody MillimanBaton Rouge$7K
- Constance BluntBaton Rouge$4K
- Daniel JohnsonNew Orleans$329K
- Laura FinnNew Orleans$171K
- Agustin GarciaIndependence$13K
- Elizabeth LejeuneLafayette$6K
- Joseph BrierreLafayette$5K
- Srikanth TammaNew Orleans$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.